Background: Previous research has established that treating COVID-19 hospitalized patients with remdesivir (RDV) was associated with significantly lower hospital readmission rates. We extend prior research with an additional year of more recent data by examining the association between RDV use and 30-day readmission rates due to any cause as well as due to COVID-19 among [...]

Background: Contemporary treatment for COVID-19 includes the use of SARS-2-CoV direct-acting antivirals (DAAs). An FDA assessment in the Medicare and Veterans Affairs population has suggested that individual agents in this class have significant differences in drug-drug interaction (DDI) potential based on their pharmacokinetic profiles; however, the clinical impact is not well established. We sought to [...]